Research programme: anti-inflammatory therapeutics - Janssen Biotech/Vectura
Latest Information Update: 09 Jan 2015
At a glance
- Originator Janssen Biotech; Vectura
- Developer Vectura
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Asthma; Chronic obstructive pulmonary disease
Most Recent Events
- 06 Jan 2015 Preclinical trials in Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 06 Jan 2015 Preclinical trials in Asthma in United Kingdom (Inhalation)